News / Blog
May Holidays 2023 - Pay Attention!
Nexavar tablets 200 mg for carcinoma (sorafenib tosylate, sorafenib tosilate)
Product Code :
Availability : 6
General information on Japanese Nexavar tablets 200 mg for carcinoma (sorafenib tosylate, sorafenib tosilate)
Package details: 56 tablets
Manufacturer: Bayer Yakuhin, Ltd., Japan
Active ingredients: sorafenib tosylate (chemical formula C28H24ClF3N4O6S)
Medical effect: Nexavar tablets are effective for the treatment of following diseases:
- unresectable renal cell carcinoma,
- metastatic renal cell carcinoma,
- unresectable hepatocellular carcinoma,
- unresectable thyroid carcinoma.
Contraindications and precautions: do not use for the pregnant, possibly pregnant or breastfeeding women. Female patients should use an effective contraceptive method due to the teratogenic effect.
Avoid taking this medicine 1 hour before and 2 hours after high-fat meals as high-fat diets may reduce its effectiveness.
If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.
Dosage and administration of Nexavar tablets 200 mg from Japan for carcinoma (sorafenib tosilate)
For adults, take 2 tablets (400 mg as sorafenib) at a time 2 times a day. The doctor in charge may decrease the dosage according to patient’s symptoms.
How effective are Nexavar tablets 200 mg from Japan for carcinoma (sorafenib tosylate)?
Nexavar tablets contain a tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis. It works by blocking the enzyme kinase, a component of the signaling pathway that controls cell division and proliferation. Also, Nexavar tablets inhibit the signaling cascade and block tumor angiogenesis.
Who should use Nexavar tablets 200 mg from Japan?
Nexavar tablets are effective for the treatment of unresectable and/or metastatic renal cell carcinoma, unresectable hepatocellular carcinoma, and unresectable thyroid carcinoma. Studies showed that sorafenib tosylate has an acceptable and highly predictable toxicity profile and is non-cross-resistant with other molecularly targeted agents (C. Porta, C. Paglino et al. “Sorafenib tosylate in advanced kidney cancer: past, present and future”. Anti-Cancer Drugs, 2009, 20 (6), pp. 409-415). In other words, this medicine is relatively safe, can be used in combination with other preparations or solely, when other preparations failed.